Header Logo

Connection

DAVID LONARD to Cell Line

Back to Details
This is a "connection" page, showing publications DAVID LONARD has written about Cell Line.
DAVID LONARD
Connection Strength
0.103
Cell Line
  1. Lead Compound Development of SRC-3 Inhibitors with Improved Pharmacokinetic Properties and Anticancer Efficacy. J Med Chem. 2024 04 11; 67(7):5333-5350.
    View in: PubMed
    Score: 0.038
  2. CAPER is vital for energy and redox homeostasis by integrating glucose-induced mitochondrial functions via ERR-a-Gabpa and stress-induced adaptive responses via NF-?B-cMYC. PLoS Genet. 2015 Apr; 11(4):e1005116.
    View in: PubMed
    Score: 0.021
  3. Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1. Cancer Res. 2014 Mar 01; 74(5):1506-1517.
    View in: PubMed
    Score: 0.019
  4. Atypical protein kinase C regulates dual pathways for degradation of the oncogenic coactivator SRC-3/AIB1. Mol Cell. 2008 Feb 29; 29(4):465-76.
    View in: PubMed
    Score: 0.013
  5. A repressive role for prohibitin in estrogen signaling. Mol Endocrinol. 2008 Feb; 22(2):344-60.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.